Vivimed Labs’ API manufacturing facility at Cuernavaca, Mexico, was recently inspected by the USFDA in compliance with their requirements. The inspection was successful, and the company obtained the Establishment Inspection Report. Shares of Vivemed Labs edged down 1.42 per cent at ₹38.30 on the NSE.
Company news: Vivimed Labs
Published on
October 5, 2018 15:26
Tags